Journal of Alzheimer's Disease

White matter injury linked to older-appearing brains

Among 601 people, each unit increase in white matter injury on a logarithmic scale was linked to a 6.95-year larger brain-age gap.

Paper by Iman Beheshti, Odelia Elkana · Red River College Polytechnic
Figure 1 from Journal of Alzheimer's Disease
Open the figure at full size
Figure 1. Beheshti et al., CC BY-NC
Cross-sectional study of 601 people with complete dataBiomarkers

Cohort study

Limit: Scan-predicted brain age is a structural proxy, not a direct measure of biological aging

Edited by Boris Djordjevic · AgingResearch.News

Follow

In an observational study of 601 people with complete data, greater injury to white matter—the brain’s nerve-fiber tissue—was associated with older-appearing brain structure. Researchers measured injury using brain scans and compared scan-predicted brain age with actual age. They expressed injury burden on a logarithmic scale, which compresses large differences.

Among 369 participants, a larger brain-age gap was linked to faster declines in memory and executive function, the ability to plan and manage tasks. Among 201 participants with mild cognitive impairment, or problems with memory or thinking, it was associated with progression to Alzheimer’s disease. That association persisted in a subset after accounting for amyloid and tau status—indicators of Alzheimer’s-related proteins—assessed before the outcome. Cardiovascular risk was not associated with this white matter injury measure.

Why it matters

The work addresses a question in brain aging: whether brain structure adds information about future cognitive decline beyond Alzheimer’s-related protein measurements.

Caveats

These observational analyses cannot establish cause and effect; the progression result concerns people who already had mild cognitive impairment. The abstract does not report participants’ ages or follow-up duration.

Where the evidence stands

MAPT

  • 81 independent labs in 26 countries
  • 7 findings against
  • 9 trials
  • Funders: National Institute on Aging and others
  • 23 of 200 findings with company ties
  • 9 of 9 trials sponsored by developers of drugs on it

Comments

Be the first to comment.